[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-356278-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-356278-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","development-and-validation-of-a-predictive-model-for-high-risk-immune-related-adverse-events-in-gastric-cancer-patients-treated-with-icis","Development and validation of a predictive model for high-risk immune-related adverse events in gastric cancer patients treated with ICIs","","Immune checkpoint inhibitors (ICIs) can trigger immune-related adverse events (irAEs), from mild to life-threatening outcomes. High-risk irAEs may cause treatment discontinuation and raise mortality, yet dependable biomarkers for predicting onset and severity remain lacking. This study analyzes accessible biomarkers linked to high-risk irAEs in gastric cancer patients treated with ICIs and develops a predictive model to quantify risk.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/development-and-validation-of-a-predictive-model-for-high-risk-immune-related-adverse-events-in-gastric-cancer-patients-treated-with-icis/356278/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/development-and-validation-of-a-predictive-model-for-high-risk-immune-related-adverse-events-in-gastric-cancer-patients-treated-with-icis/356278.png","ImageObject",300,407,{"name":42,"@type":43},"Finn","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-30","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why are high-risk immune-related adverse events important in ICIs treatment?","Question",{"text":63,"@type":64},"High-risk irAEs can lead to treatment discontinuation and higher mortality, making prediction and management clinically critical.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What data period and patient cohort were used to build the model?",{"text":68,"@type":64},"Data were collected from gastric cancer patients receiving ICIs therapy between May 2020 and March 2025, totaling 184 enrolled patients.",{"name":70,"@type":61,"acceptedAnswer":71},"Which biomarkers and factors were identified as independent predictors of grade ≥3 irAEs?",{"text":72,"@type":64},"Multivariate logistic regression identified NLR-1, NLR2-1, PLR-1, tumor thickness, CV, and intratumoral necrosis as independent predictors.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},356278,1790465089,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},34359740700684,"https://ap-avatar.wpscdn.com/avatar/1f400023980c374ae676?_k=1777273430885731487","HUMAN VACCINES & IMMUNOTHERAPEUTICS 2026, VOL. 22, NO. 1, 2610907 [https://doi.org/10.1080/21645515.2025.2610907](https://doi.org/10.1080/21645515.2025.2610907)  \nRESEARCH ARTICLE     \nDevelopment and validation of a predictive model for high-risk  \nimmune-related adverse events in gastric cancer patients treated with ICIs  \nLi Maa,b, Junbo Wub, Yunyi Duc, Min Liuc, Wenqing Hud, Jun Zhaoc, and Yong'ai Li b  \naDepartment of Radiology, Third Clinical College, Changzhi Medical College, Changzhi, Shanxi, China; bDepartment of Radiology, Changzhi People’s Hospital Affiliated to Changzhi Medical College, Changzhi, Shanxi, China; cDepartment of Oncology, Changzhi People’s Hospital Affiliated to Changzhi Medical College, Changzhi, Shanxi, China; dDepartment of Gastrointestinal Surgery, Changzhi People’s Hospital Affiliated to Changzhi Medical College, Changzhi, Shanxi, China  \nABSTRACT  \nImmune checkpoint inhibitors (ICIs) may cause immune-related adverse events (irAEs), ranging from mild to life-threatening. High-risk irAEs can lead to treatment discontinuation and higher mortality, though ICI-treated patients’ death rate is under 5% . Currently, no reliable biomarkers predict irAEs’ occurrence or severity. This study investigates the link between accessible biomarkers and high-risk irAEs in gastric cancer patients on ICIs, as well as to develop and assess a predictive model for such events. Data were collected from patients with gastric cancer who received ICIs therapy between May 2020 and March 2025. The incidence and risk factors associated with irAEs were analyzed using the chi-square test or the Mann–Whitney U test. Univariate and multivariate logistic regression analyses were conducted to develop a predictive model. This model was validated through 10-fold cross-validation and assessed using the area under the receiver operating characteristic curve (AUC), sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV), calibration curves, and decision curve analysis. A total of 184 gastric cancer patients receiving ICIs therapy were enrolled in this study. The incidence of irAEs of any grade was 21.2%, while the incidence of grade ≥3 irAEs was 12.5% . Multivariate logistic regression analysis identified NLR-1 (p \u003C .001), NLR2-1 (p \u003C .001), PLR-1 (p = .001), tumor thickness (p = .018), CV (p = .001), and intratumoral necrosis (p = .028) as independent predictors of grade ≥3 irAEs. The AUC of the developed model was 0.878, with a sensitivity of 78.26%, specificity of 80.12%, PPV of approximately 80.95%, and NPV of approximately 75.52% . The corrected C-index, derived from bootstrap resampling, was 0.849, and both calibration curves and decision curve analysis confirmed good calibration and clinical utility. These predictors may aid risk stratification and optimized patient management.  \nARTICLE HISTORY  \nReceived 30 September 2025 Revised 17 December 2025 Accepted 26 December 2025  \nKEYWORDS  \nImmune checkpoint inhibitors (ICIs); immunerelated adverse events (irAEs); gastric cancer (GC); prediction model; complete blood cell (CBC)  \nIntroduction  \nGastric cancer (GC) ranks among the top five in both incidence and mortality among malignant tumors globally.1 While immune checkpoint inhibitors (ICIs) offer promising treatment options for GC,2–4 Among these therapies, PD-1/PD-L1 inhibitors have emerged as the core regimen in clinical practice – the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Gastric Cancer (2025 Version 2)5 has explicitly recommended them as the standard first-line, second-line, and beyond treatment for advanced gastric cancer. Not all patients benefit, and some may experience immune-related adverse events (irAEs), which require careful monitoring and management.6 Mild irAEs are generally manageable, but severe cases can lead to treatment discontinuation and increased mortality.7  \nResearch on biomarkers to predict irAEs is growing,8 with blood cell analysis bei","cbCait3LaOulx5qc","https://ap.wps.com/l/cbCait3LaOulx5qc","pdf",3216282,13,"English","# Introduction\n# Methods\n## Statistical analyses and model development\n## Validation and performance evaluation\n# Results\n## Incidence of irAEs\n## Independent predictors for grade ≥3 irAEs\n## Predictive performance\n# Conclusion","[{\"question\":\"Why are high-risk immune-related adverse events important in ICIs treatment?\",\"answer\":\"High-risk irAEs can lead to treatment discontinuation and higher mortality, making prediction and management clinically critical.\"},{\"question\":\"What data period and patient cohort were used to build the model?\",\"answer\":\"Data were collected from gastric cancer patients receiving ICIs therapy between May 2020 and March 2025, totaling 184 enrolled patients.\"},{\"question\":\"Which biomarkers and factors were identified as independent predictors of grade ≥3 irAEs?\",\"answer\":\"Multivariate logistic regression identified NLR-1, NLR2-1, PLR-1, tumor thickness, CV, and intratumoral necrosis as independent predictors.\"}]","Development and validation of a predictive model for high-risk immune-related adverse events in gastric cancer patients treated with ICIs | PDF",1790124391,33,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0d139b6b17fc0c3b78e85c5a05049dfc.webp",983,1310,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5382187179ccd38b3b69ad92077bc0af.webp",982,1309,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9a0565adcafa269fd2bb4879256b0900.webp",981,1308,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/604b16c2a7fc391b33469705686b2c61.webp",980,1306]